Amendments to the Claims:

This listing of the claims will replace all prior versions and listing of claims in the application.

Please amend claim 75 and add new claims 156 to 165 as follows.

1 to 74. (cancelled)

75. (currently amended) A method of delivering a drug to a subject comprising administering to the subject a ~~therapeutically effective amount of a~~ pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a chimeric protein comprising (i) a first protein comprising six contiguous amino acids of the amino acid sequence of SEQ ID NO: 51, said contiguous amino acids being capable of specifically binding to the gastro-intestinal receptor HPT1 (SEQ ID NO: 178), said first protein being fused via a covalent bond to a second protein, ~~being a~~ wherein the second protein acts as a drug; and (ii) a pharmaceutically acceptable carrier.

76 to 108. (cancelled)

109. (previously presented) A method of delivering an active agent in vivo comprising administering to a subject a composition comprising a purified protein which specifically bind the gastro-intestinal tract receptor HPT1 (SEQ ID NO: 178), wherein the purified protein is bound to a material comprising an active agent selected from the group consisting of an imaging agent, a drug, and an antigen and wherein the purified protein comprises the amino acid sequence of SEQ ID NO: 51 or a portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.

110. (previously presented) The method of claim 109 wherein the purified protein comprises the amino acid sequence of SEQ ID NO: 51.

111 to 116 (cancelled)

117. (previously presented) The method of claim 109 wherein the material is a particle containing the active agent.

118. (previously presented) The method of claim 109 wherein the active agent is a drug.

119. (previously presented) The method as in any one of claims 109 and 117-118 wherein the purified protein is not more than 40 amino acid in length.

120. (previously presented) The method as in any one of claims 109 and 117-118 wherein the purified protein is not more than 30 amino acids in length.

121. (previously presented) The method as in any one of claims 109 and 117-118 wherein the purified protein is not more than 20 amino acids in length.

122. (previously presented) The method as in any one of claims 109, 110 and 117-118 wherein said purified protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.

123. (previously presented) The method as in any one of claims 109, 110 and 117-118, in which the administering is oral.

124. (previously presented) The method as in any one of claims 109, 110 and 117-118, in which the active agent is a drug.

125. (previously presented) The method as in any one of claims 109, 110 and 117-118, in which the subject is human.

126. (previously presented) The method of claim 124, in which the subject is human.

127. (previously presented) A method of delivering a drug to a subject comprising administering to the subject a composition comprising a purified protein which specifically bind the gastro-intestinal tract receptor HPT1 (SEQ ID NO: 178), wherein the purified protein is covalently bound to a particle containing a drug of value in the treatment of a mammalian disease or disorder, and wherein the purified protein comprises the amino acid sequence of SEQ ID NO: 51 or a portion thereof of at least 6 contiguous

amino acids that mediates binding to HPT1.

128. (previously presented) The method of claim 127 wherein the protein comprises the amino acid sequence of SEQ ID NO: 51.

129 to 134 (cancelled)

135. (previously presented) The method of claim 127 wherein the purified protein is not more than 40 amino acids in length.

136. (previously presented) The method of claim 127 wherein the purified protein is not more than 30 amino acids in length.

137. (previously presented) The method of claim 127 wherein the purified protein is not more than 20 amino acids in length.

138. (previously presented) The method as in any one of claims 127-128 wherein said purified protein facilitates the transport of the drug through human or animal gastro-intestinal tissue.

139. (previously presented) The method as in any one of claims 127-128 in which the administering is oral.

140. (previously presented) The method as in any one of claims 127-128 in which the subject is human.

141. (previously presented) A method of delivering a drug to a subject comprising administering to the subject a composition comprising a purified protein which specifically binds the gastro-intestinal tract receptor HPT1 (SEQ ID NO: 178), wherein the purified protein is covalently bound to a drug of value in the treatment of a mammalian disease or disorder, and wherein the purified protein comprises the amino acid sequence of SEQ ID NO: 51 or a portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.

142. (previously presented) The method of claim 141 wherein the protein comprises the amino acid sequence of SEQ ID NO: 51.

143 to 148 (cancelled)

149. (previously presented) The method of claim 141 wherein the purified protein is not more than 40 amino acids in length.

150. (previously presented) The method of claim 141 wherein the purified protein is not more than 30 amino acids in length.

151. (previously presented) The method of claim 141 wherein the purified protein is not more than 20 amino acids in length.

152. (previously presented) The method as in any one of claims 141-142 wherein said purified protein facilitates the transport of the drug through human or animal gastro-intestinal tissue.

153. (previously presented) The method as in any one of claims 141-142 in which the administering is oral.

154. (previously presented) The method as in any one of claims 141-142 in which the subject is a human.

155. (previously presented) The method of claim 75, wherein the first protein comprises 10 contiguous amino acids of the amino acid sequence of SEQ ID NO: 51.

156. (new) A method of delivering a drug to a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a chimeric protein comprising (i) a first protein comprising the amino acid sequence of SEQ ID NO: 51, said first protein being fused via a covalent bond to a second protein, wherein the second protein acts as a drug; and (ii) a pharmaceutically acceptable carrier.

157. (new) A method of delivering an active agent in vivo comprising administering to a subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, wherein the isolated protein is bound to a material comprising an active agent selected from the group consisting of an antigen, imaging agent and drug.

158. (new) A method of delivering a drug to a subject comprising administering to the subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, wherein the isolated protein is covalently bound to a particle containing the drug.

159. (new) A method of delivering a drug to a subject comprising administering to the subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, wherein the isolated protein is covalently bound to the drug.

160. (new) The method of claim 157 wherein the active agent is a drug.

161. (new) The method of claim 157 wherein the material is a particle containing the active agent.

162. (new) The method as in any one of claims 157 to 159 wherein the isolated protein consists essentially of the amino acid sequence of SEQ ID NO: 51.

163. (new) The method as in any one of claims 157 to 159 wherein the isolated protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.

164. (new) The method as in any one of claims 156 to 159 wherein the administration is oral.

165. (new) The method as in any one of claims 156 to 159 wherein the subject is human.